168 related articles for article (PubMed ID: 24371765)
1. Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones.
Andersen CL; Asmar F; Klausen T; Hasselbalch H; Grønbæk K
Leuk Res Rep; 2012; 2(1):1-3. PubMed ID: 24371765
[TBL] [Abstract][Full Text] [Related]
2. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
[TBL] [Abstract][Full Text] [Related]
3. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.
Veazey KJ; Cheng D; Lin K; Villarreal OD; Gao G; Perez-Oquendo M; Van HT; Stratton SA; Green M; Xu H; Lu Y; Bedford MT; Santos MA
Leukemia; 2020 Dec; 34(12):3269-3285. PubMed ID: 32576962
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
[TBL] [Abstract][Full Text] [Related]
5. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
Meyer SN; Scuoppo C; Vlasevska S; Bal E; Holmes AB; Holloman M; Garcia-Ibanez L; Nataraj S; Duval R; Vantrimpont T; Basso K; Brooks N; Dalla-Favera R; Pasqualucci L
Immunity; 2019 Sep; 51(3):535-547.e9. PubMed ID: 31519498
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.
Nie M; Du L; Ren W; Joung J; Ye X; Shi X; Ciftci S; Liu D; Wu K; Zhang F; Pan-Hammarström Q
Cell Death Dis; 2021 Apr; 12(5):419. PubMed ID: 33911074
[TBL] [Abstract][Full Text] [Related]
7. Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms.
Andersen CL; Hasselbalch H; Grønbæk K
Leuk Res; 2012 Apr; 36(4):485-7. PubMed ID: 22177454
[TBL] [Abstract][Full Text] [Related]
8. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
9. Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer.
Duex JE; Swain KE; Dancik GM; Paucek RD; Owens C; Churchill MEA; Theodorescu D
Mol Cancer Res; 2018 Jan; 16(1):69-77. PubMed ID: 28970362
[TBL] [Abstract][Full Text] [Related]
10. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
Thompson RC; Vardinogiannis I; Gilmore TD
PLoS One; 2013; 8(5):e62822. PubMed ID: 23667527
[TBL] [Abstract][Full Text] [Related]
11. Confirmation of EP300 gene mutations as a rare cause of Rubinstein-Taybi syndrome.
Zimmermann N; Acosta AM; Kohlhase J; Bartsch O
Eur J Hum Genet; 2007 Aug; 15(8):837-42. PubMed ID: 17299436
[TBL] [Abstract][Full Text] [Related]
12. Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma.
Wei W; Song Z; Chiba M; Wu W; Jeong S; Zhang JP; Kadin ME; Nakagawa M; Yang Y
Leukemia; 2023 Feb; 37(2):396-407. PubMed ID: 36456744
[TBL] [Abstract][Full Text] [Related]
13. Effects of the omega-3 fatty acid DHA on histone and p53 acetylation in diffuse large B cell lymphoma.
Bakhshi TJ; Way T; Muncy B; Georgel PT
Biochem Cell Biol; 2023 Apr; 101(2):172-191. PubMed ID: 36599133
[TBL] [Abstract][Full Text] [Related]
14. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
Qian M; Zhang H; Kham SK; Liu S; Jiang C; Zhao X; Lu Y; Goodings C; Lin TN; Zhang R; Moriyama T; Yin Z; Li Z; Quah TC; Ariffin H; Tan AM; Shen S; Bhojwani D; Hu S; Chen S; Zheng H; Pui CH; Yeoh AE; Yang JJ
Genome Res; 2017 Feb; 27(2):185-195. PubMed ID: 27903646
[TBL] [Abstract][Full Text] [Related]
15. CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma.
Sun Y; Gao Y; Chen J; Huang L; Deng P; Chen J; Chai KXY; Hong JH; Chan JY; He H; Wang Y; Cheah D; Lim JQ; Chia BKH; Huang D; Liu L; Liu S; Wang X; Teng Y; Pang D; Grigoropoulos NF; Teh BT; Yu Q; Lim ST; Li W; Ong CK; Huang H; Tan J
Cancer Lett; 2021 Sep; 521():268-280. PubMed ID: 34481935
[TBL] [Abstract][Full Text] [Related]
16. CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; González-Corpas A; Barrero MJ
Mol Cancer Res; 2019 Mar; 17(3):720-730. PubMed ID: 30606771
[TBL] [Abstract][Full Text] [Related]
17. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.
Mondello P; Tadros S; Teater M; Fontan L; Chang AY; Jain N; Yang H; Singh S; Ying HY; Chu CS; Ma MCJ; Toska E; Alig S; Durant M; de Stanchina E; Ghosh S; Mottok A; Nastoupil L; Neelapu SS; Weigert O; Inghirami G; Baselga J; Younes A; Yee C; Dogan A; Scheinberg DA; Roeder RG; Melnick AM; Green MR
Cancer Discov; 2020 Mar; 10(3):440-459. PubMed ID: 31915197
[No Abstract] [Full Text] [Related]
18. The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies.
Zhu Y; Wang Z; Li Y; Peng H; Liu J; Zhang J; Xiao X
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831561
[TBL] [Abstract][Full Text] [Related]
19. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
[TBL] [Abstract][Full Text] [Related]
20. Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines.
Tillinghast GW; Partee J; Albert P; Kelley JM; Burtow KH; Kelly K
Genes Chromosomes Cancer; 2003 Jun; 37(2):121-31. PubMed ID: 12696060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
